Classical live viral vaccines

Birkhauser Advances in Infectious Diseases

Volumn , Issue , 2011, Pages 47-69

  Monath, Thomas P ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; SMALLPOX VACCINE; VIRUS VACCINE; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG SAFETY; GENOMIC INSTABILITY; HUMAN; IMMUNOGENICITY; MICROBIAL CONTAMINATION; MUCOSAL IMMUNITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SHOCK; THERMOSTABILITY; TOXIC HEPATITIS; VIREMIA; VIRUS ATTENUATION; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; VISCERAL PROLAPSE;

EID: 79960065340     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0277-8_3     Document Type: Article

References (102)

1. Sawyer WA, Kitchen SF, Lloyd W (1931) Vaccination of humans against yellow fever with immune serum and virus fixed for mice. Proc Soc Exp Biol Med 29:62-64
2. Theiler M, Smith HH (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65:787-800 Classical Live Viral Vaccines 63
3. Smorodintsev AA, Tsushinky MD, Drobyshevskaya AI, Korovin AA (1937) Investigation on volunteers infected with the influenza virus. Am J Med Sci 194:159-170
4. Kolmer JA (1935) Susceptibility and immunity in relation to vaccination in acute anterior poliomyelitis. JAMA 105:1956-1963
5. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC (1999) Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73:8356-8363
6. Norrby E (2007) Historical Feature. Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J Exp Med 204:2779-2784
7. Koprowski H (1955) Immunization of man with living poliomyelitis virus. Monogr Ser World Health Organ 26:335-356
8. Enders JF, Katz SL, Milovanovic MV, Holloway A (1960) Studies on an attenuated measles virus-vaccine. 1. Development and preparation of the vaccine: techniques for assay of effects of vaccination. N Engl J Med 263:153-159
9. Maassab HF, DeBorde DC (1985) Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3:355-369
10. Theiler M, Smith HH (1937) Effect of prolonged cultivation in vitro upon pathogenicity of yellow fever virus. J Exp Med 65:767-786
11. Stokes J Jr, Weibel RE, Buynak EB, Hilleman MR (1967) Live attenuated mumps virus vaccine. II. Early clinical studies. Pediatrics 39:363-371
12. Monath TP, Cetron M, Teuwen D (2008) Yellow fever. In: Plotkin S, Orenstein W, Offit P (eds) Vaccines, 5th edn. Saunders Elsevier, Philadelphia, pp 959-1055
13. Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K (2003) Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental viruses. J Virol 77:3351
14. Kakizawa J, Nitta Y, Yamashita T, Ushijima H, Katow S (2001) Mutations of rubella virus vaccine TO-336 strain occurred in the attenuation process of wild progenitor virus. Vaccine 19:2793-2802
15. Ren R, Moss EG, Racaniello VR (1991) Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 65:1377-1382
16. Omata T, Kohara M, Kuge S, Komatsu T, Abe S, Semler BL, Kameda A, Itoh H, Arita M, Wimmer E (1986) Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol 58:348-358
17. ®) in a Phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66:533-541
18. Monath TP (1971) Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol 93:122-129
19. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981) Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59:895-900
20. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R (2008) Human effector and memory CD8{thorn} T cell responses to smallpox and yellow fever vaccines. Immunity 28:710-722
21. Scherer CA, Magness CL, Steiger KV, Poitinger ND, Caputo CM, Miner DG, Winokur PL, Klinzman D, McKee J, Pilar C, Ward PA, Gillham MH, Haulman NJ, Stapleton JT, Iadonato SP (2007) Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. Vaccine 25:6458-6473
22. Querec TD, Akindy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10:116-125
23. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR 3rd, Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Haddad EK, Sékaly RP (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131
24. Barba-Spaeth G, Longman RS, Albert ML, Rice CM (2005) Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202:1179-1184
25. Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, Barvir D, Gunther V, Burgess T, Kohno Y, Padmanabhan R, Sun W (2007) Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88:148-156
26. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:413-424
27. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18:899-906
28. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM (2006) Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80:11756-11766
29. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, Wolff M (2000) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181:1133-1137
30. Kaul D, Ogra PL (1998) Mucosal responses to parenteral and mucosal vaccines. Dev Biol Stand 95:141-146
31. Bellanti JA, Zeligs BJ, Mendez-Inocencio J, García-Garcia ML, Islas-Romero R, Omidvar B, Omidvar J, Kim G, Fernandez De Castro J, Sepulveda Amor J, Walls L, Bellini WJ, Valdespino-Gomez JL (2004) Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 22:1214-1220
32. World Health Organization (1987) Poliomyelitis in 1985-1989. Wkly Epidemiol Rec 62:273-280
33. Duclos P, Okwo-Bele JM, Gacic-Dobo M, Cherian T (2009) Global immunization: status, progress, challenges and future. BMC Int Health Hum Rights 9(Suppl 1):S2
34. Patriarca PA, Wright PF, John TJ (1991) Factors affecting the immunogenicity of oral poliovirus in developing countries: review. Rev Infect Dis 13:926-939
35. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L (1998) Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 47(RR-8):1-57
36. Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP (2009) Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 27:1637-1644
37. Stark JH, Frey SE, Blum PS, Monath TP (2006) Lack of transmission of vaccinia virus. Emerg Infect Dis 12:698-700
38. Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Oro JB, Ben-Porath E, Rennick V (1967) Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 86:112-136
39. MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, O'Leary P, Thompson RA, Osman H, Wood P, Minor P, Wood DJ, Pillay D (2004) Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509-1513
40. To KK, Chan KH, Li IW, Tsang TY, Tse H, Chan JF, Hung IF, Lai ST, Leung CW, Kwan YW, Lau YL, Ng TK, Cheng VC, Peiris JS, Yuen KY (2010) Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol 82:1-7
41. Hammitt LL, Bartlett JP, Li S, Rahkola J, Lang N, Janoff EN, Levin MJ, Weinberg A (2009) Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. Vaccine 27:7359-7366
42. Murphy BR, Rennels MB, Douglas RG Jr, Betts RF, Couch RB, Cate TR Jr, Chanock RM, Kendal AP, Maassab HF, Suwanagool S, Sotman SB, Cisneros LA, Anthony WC, Nalin DR, Levine MM (1980) Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and coldadapted recombinant viruses in seronegative adult volunteers. Infect Immun 29:348-355
43. Morfin F, Beguin A, Lina B, Thouvenot D (2002) Detection of measles vaccine in the throat of a vaccinated child. Vaccine 20:1541-1543
44. Permar SR, Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE (2001) Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis 183:532-538
45. Rota PA, Khan AS, Durigon E, Yuran T, Villamarzo YS, Bellini WJ (1995) Detection of measles virus RNA in urine specimens from vaccine recipients. J Clin Microbiol 33:2485-2488
46. Polgreen PM, Bohnett LC, Cavanaugh JE, Gingerich SB, Desjardin LE, Harris ML, Quinlisk MP, Pentella MA (2008) The duration of mumps virus shedding after the onset of symptoms. Clin Infect Dis 46:1447-1449
47. Sawada H, Yano S, Oka Y, Togashi T (1993) Transmission of Urabe mumps vaccine between siblings. Lancet 342:371
48. Atrasheuskaya AV, Neverov AA, Rubin S, Ignatyev GM (2006) Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine 24:1530-1536
49. Tsolia M, Gershon AA, Steinberg SP, Gelb L (1990) Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National institute of allergy and infectious diseases Varicella vaccine collaborative study group. J Pediatr 116:184-189
50. Whitman L (1939) Failure of Aedes aegypti to transmit yellow fever cultured virus (17D). Am J Trop Med Hyg 19:16-19
51. Manrubia SC, Escarmís C, Domingo E, Lázaro E (2005) High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. Gene 347:273-282
52. Drake JW, Charlesworth B, Charlesworth D, Crow JF (1998) Rates of spontaneous mutation. Genetics 148:1667-1686
53. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, Girakhoo S, Pougatcheva SO, Arroyo J, Trent DW, Monath TP (2004) High fidelity of yellow fever virus RNA polymerase. J Virol 78:1032-1038
54. Shah D, Vidal S, Link MA, Rubin SA, Wright KE (2009) Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus. J Med Virol 81:130-138
55. Fox JP, Lennette EH, Manso C (1942) Encephalitis in man following vaccination with 17D yellow fever virus. Am J Hyg 36:117-142
56. Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson AJ (1988) Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 6:513-518
57. Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran YX, Levenbook IS (1992) RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol 66:966-970
58. Chumakov K, Norwood L, Parker M, Dragunsky E, Taffs R, Ran Y, Ridge J, Levenbook I (1993) Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence. Dev Biol Stand 78:79-89
59. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW (2004) Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292:1696-1701
60. Macadam AJ, Arnold C, Howlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J et al (1989) Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccines. Virology 172:408-414
61. Kapusinszky B, Molnár Z, Szomor KN, Berencsi G (2009) Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol 58(2):211-217
62. Friedrich F (1996) Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virol 40:157-170
63. Jennings AD, Gibson CA, Miller BR, Matthews JH, Mitchell CJ, Roehrig JT, Wood DJ, Taffs F, Sil BK, Whitby SN, Whitby JE, Monath TP, Minor PD, Sanders PG, Barrett ADT (1994) Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 169:512-518
64. Lin YH, Deatly AM, Chen W, Miller LZ, Lerch R, Sidhu MS, Udem SA, Randolph VB (2006) Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates. Virus Res 115:9-15
65. Minor PD, Dunn G (1988) The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut. J Gen Virol 69:1091-1096
66. Krugman RD, Meyer BC, Enterline JC, Parkman PD, Witte JJ, Meyer HM Jr (1974) Impotency of live-virus vaccines as a result of improper handling in clinical practice. J Pediatr 85:512-514
67. Kuno-Sakai H, Kimura M (2003) Removal of gelatin from live vaccines and DTaP-an ultimate solution for vaccine-related gelatin allergy. Biologicals 31:245-249
68. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, Nichols R, Johnson C, Cruz J, Kennedy JS, Ennis FA, Monath TP (2003) Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9:1125-1130
69. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, Kemp T, Nichols R, Weltzin R (2004) ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8(Suppl 2):31-44
70. Harris RJ, Dougherty RM, Biggs PM et al (1966) Contaminant viruses in two live virus vaccines produced in chick cells. J Hyg (Lond) 64:1-7
71. Waters TD, Anderson PS Jr, Beebe GW, Miller RW (1972) Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 177:76-77
72. Weiss RA (2001) Adventitious viral genomes in vaccines but not in vaccinees. Emerg Infect Dis 7:153-154
73. Hussain AI, Johnson JA (2003) Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J Virol 77:1105-1111
74. Findlay GM, MacCallum FO (1938) Hepatitis and jaundice associated with immunization against certain virus diseases. Proc R Soc Med 31:799-806
75. Fox JP, Manso C, Penna HA et al (1942) Observations on the occurence of icterus in Brazil following vaccination against yellow fever. Am J Hyg 36:68-116
76. Sawyer WA, Meyer KF, Eaton MD (1944) Jaundice in Army personnel in western region of United States and its relation to vaccination against yellow fever. Am J Hyg 40:35-107
77. Seeff LB, Beebe GW, Hoofnagle JH (1987) A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the US Army. N Engl J Med 316:965-970
78. Norman JE, Beebe GW, Hoofnagle JH, Seeff LB (1993) Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army. Hepatology 18:790-797
79. Studer E, Bertoni G, Candrian U (2002) Detection and characterization of pestivirus contaminations in human live viral vaccines. Biologicals 30:289-296
80. Giangaspero M, Vacirca G, Harasawa R, Bttner M, Panuccio A, De Giuli MC, Zanetti A, Belloli A, Verhulst A (2001) Genotypes of pestivirus RNA detected in live virus vaccines for human use. J Vet Med Sci 63:723-733
81. Audet SA, Crim RL, Beeler J (2000) Evaluation of vaccines, interferons and cell substrates for pestivirus contamination. Biologicals 28:41-46
82. Giangaspero M, Vacirca G, Morgan D, Baboo KS, Luo NP, DuPont HL, Zumla A (1993) Anti-bovine viral diarrhoea virus antibodies in adult Zambian patients infected with the human immunodeficiency virus. Int J STD AIDS 4:300-302
83. Yolken R, Dubovi E, Leister F, Reid R, Almeido-Hill J, Santosham M (1989) Infantile gastroenteritis associated with excretion of pestivirus antigens. Lancet 1:517-520
84. Giangaspero M, Harasawa R, Verhulst A (1997) Genotypic analysis of the 5'-untranslated region of a pestivirus strain isolated from human leucocytes. Microbiol Immunol 41:829-834
85. Nims RW (2006) Detection of adventitious viruses in biologicals-a rare occurrence. Dev Biol (Basel) 123:153-164, discussion 183-197
86. Sexton DJ, Rollin PE, Breitschwerdt EB, Corey GR, Myers SA, Dumais MR, Bowen MD, Goldsmith CS, Zaki SR, Nichol ST, Peters CJ, Ksiatek TG (1997) Life-threatening Cache Valley virus infection. N Engl J Med 336:547-549
87. Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni JF Jr, Goedert JJ (1998) Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 279:292-295
88. Klein G, Powers A, Croce C (2002) Association of SV40 with human tumors. Oncogene 21:1141-1149
89. Lee W, Langhoff E (2006) Polyomavirus in human cancer development. Adv Exp Med Biol 577:310-318
90. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB (2008) Adverse event reports following yellow fever vaccination. Vaccine 26:6077-6082
91. Hayes EB (2007) Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 101:967-971
92. Galler R, Pugachev KV, Santos CLS, Ochran S, Jabor AV, Rodrigues SG, Marchevsky RS, Freire MS, Almeida LFC, Cruz ACR, Yamamura AMY, Rocco IM, Travassos da Rosa ES, Souza LTM, Vasconcelos PFC, Guirakhoo F, Monath TP (2001) Phenotypic and molecular analyses of yellow fever 17DD vaccine virus associated with serious adverse events in Brazil. Virology 290:309-319
93. Whittembury A, Ramirez G, Hernández H, Ropero AM, Waterman S, Ticona M, Brinton M, Uchuya J, Gershman M, Toledo W, Staples E, Campos C, Martínez M, Chang GJ, Cabezas C, Lanciotti R, Zaki S, Montgomery JM, Monath T, Hayes E (2009) Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27:5974-5981
94. Barwick R (2004) Eidex for the yellow fever vaccine safety working group History of thymoma and yellow fever vaccination. Lancet 364:936
95. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, Glidewell J, Monson N, Zhu T, Zhu H, Staprans S, Lee D, Brinton MA, Perelygin AA, Vellozzi C, Brachman P Jr, Lalor S, Teuwen D, Eidex RB, Cetron M, Priddy F, del Rio C, Altman J, Ahmed R (2008) Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198:500-507
96. Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, Lanciotti R, Perelygin A, Zaki S, Paddock C, Querec T, Zhu T, Pulendran B, Eidex RB, Hayes E (2007) Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25:8480-8485
97. Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD (2009) A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 5(10):e1000614
98. Kengsakul K, Sathirapongsasuti K, Punyagupta S (2002) Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85:131-134
99. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA (2000) The postmarketing safety profile of varicella vaccine. Vaccine 19:916-923
100. McGee CE, Lewis MG, Claire MS, Wagner W, Lang J, Guy B, Tsetsarkin K, Higgs S, Decelle T (2008) Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 197:693-697
101. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, Pulendran B (2008) Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 9: 1157-1164
102. Timm A, Enzinger C, Felder E, Chaplin P (2006) Genetic stability of recombinant MVA-BN. Vaccine 24:4618-4621